BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 28445298)

  • 21. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
    Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
    Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
    Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
    Kudo M; Arizumi T; Ueshima K; Sakurai T; Kitano M; Nishida N
    Dig Dis; 2015 Oct; 33(6):751-8. PubMed ID: 26488473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
    Adhoute X; Pénaranda G; Raoul JL; Blanc JF; Edeline J; Conroy G; Perrier H; Pol B; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):433-40. PubMed ID: 26695429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
    Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
    Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
    Li J; Hou Y; Cai XB; Liu B
    World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
    Chan YC; Kabiling CS; Pillai VG; Aguilar G; Wang CC; Chen CL
    World J Surg; 2015 Jun; 39(6):1510-8. PubMed ID: 25665673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
    Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
    Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
    Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
    Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
    Nakazawa T; Hidaka H; Shibuya A; Okuwaki Y; Tanaka Y; Takada J; Minamino T; Watanabe M; Kokubu S; Koizumi W
    BMC Gastroenterol; 2014 May; 14():84. PubMed ID: 24886354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis.
    Ha Y; Shim JH; Kim SO; Kim KM; Lim YS; Lee HC
    J Gastroenterol Hepatol; 2014 Apr; 29(4):787-93. PubMed ID: 24224567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.
    Kimura H; Ohkawa K; Miyazaki M; Sakakibara M; Imanaka K; Tamura T; Sueyoshi H; Takada R; Fukutake N; Uehara H; Ashida R; Ioka T; Nakazawa T; Nakanishi K; Katayama K
    Hepatol Int; 2017 Jan; 11(1):105-114. PubMed ID: 27766479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH
    Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.